HPSE Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the heparanase (HPSE) gene. This polyclonal knockout model abolishes heparanase enzymatic activity, providing a genetically defined loss-of-function system for investigating HPSE-dependent processes in cancer biology and drug testing. The polyclonal nature ensures representation of diverse editing events across the population, making it suitable for bulk assays without the isolation of single-cell clones.
The A-549 cell line is a well-characterized human epithelial model derived from a lung carcinoma, retaining properties of alveolar Type II epithelial cells. It is extensively used in lung cancer research, including studies on tumor cell invasion, metastasis, drug resistance, and epithelial?Cmesenchymal transition. Its capacity to form tumors in xenograft models and its responsiveness to growth factor stimulation make it an ideal host for studying the role of extracellular matrix remodeling and angiogenic switch mechanisms.
Heparanase (HPSE) is an endoglycosidase that cleaves heparan sulfate proteoglycans, thereby releasing sequestered heparin-binding growth factors such as FGF2 and VEGF from the extracellular matrix. This enzymatic activity is triggered by upstream regulators including EGF, TNF-??, and hypoxia (HIF-1??), and leads to downstream activation of MAPK/ERK and PI3K/Akt signaling cascades. HPSE also facilitates the proteolytic activation of MMP-2 and MMP-9, promotes syndecan shedding, and enhances integrin-mediated cell adhesion and migration. By liberating matrix-bound factors, HPSE acts as a critical node connecting extracellular matrix remodeling to intracellular signaling pathways that drive proliferation, survival, and invasive behavior.
In the A-549 background, knockout of HPSE eliminates this enzymatic activity, thereby abrogating the release of FGF2, VEGF, and other growth factors from the pericellular matrix. Consequently, the polyclonal knockout cells exhibit impaired activation of ERK and Akt, reduced expression of matrix metalloproteinases, and diminished migratory and invasive capacities. This model recapitulates the loss of heparanase function in a lung adenocarcinoma setting, enabling precise dissection of HPSE-dependent contributions to tumor progression and angiogenesis. It is particularly valuable for validating the specificity of heparanase inhibitors and for exploring compensatory mechanisms in matrix degradation.
Researchers can employ these knockout cells in a broad range of functional assays, including Boyden chamber invasion assays, wound healing migration assays, and tube formation assays with endothelial cells to assess angiogenic potential. They are suitable for biochemical analyses such as Western blotting for p-ERK and p-Akt, ELISA-based quantification of VEGF release, and qPCR profiling of downstream targets. In vivo, the polyclonal knockout population can be used in xenograft models to evaluate metastatic potential and tumor angiogenesis. Additionally, co-culture systems and ECM degradation assays allow detailed study of the tumor microenvironment. For further technical details and custom inquiries, please contact Ascent Research.
